مشخصات پژوهش

Abstract Single-nucleotide substitution of FAS (rs2234767) may alter the expression of FAS gene. Recent evidence suggests association of this polymorphism with increased risk of various cancers. Therefore, this study aimed to assess the FAS promoter polymorphism (rs2234767) in thyroid cancer susceptibility in the northwestern population of Iran. Genotypes of 106 patients with thyroid cancer and 186 controls were determined for the FAS-1377G>A polymorphism by Tetra-ARMS-PCR. For statistical analysis, p<0.05 was considered as significance level. None of the genotypes of FAS-1377G/A polymorphism were associated with the risk of thyroid cancer, significantly (p>0.05). The frequency of the homozygous genotype (GG) in patients was higher rather than controls (72.64% and 65.59%, respectively). In contrast, the heterozygous genotype frequency in controls was about 5% higher rather than cases (OR=0.751, 95%CI=0.422-1.331, p=0.296). There was higher but not significant frequency for AA genotype in controls than cases (3.76% and 1.88%, respectively). According to our findings, the FAS-1377G>A polymorphism cannot be used as a molecular marker to predict thyroid cancer in the northwestern population of Iran.